A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2014
At a glance
- Drugs WBP-216 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2013 Status changed from active, no longer recruiting to discontinued, according to an AstraZeneca pipeline.
- 25 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.